Dataset opportunity
Venamed — 医疗影像数据集机会
Venamed 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
66.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场在 2025 年的估值为 21 亿美元，预计到 2035 年将达到 196 亿美元，复合年增长率为 23.9%（来源：Global Market Insights Inc.）。[3]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Venamed 持有一个重要的医疗影像数据集，包含由详细的 `iot_data`、`medical_records` 和 `procurement` 日志支持的影像模态。这些丰富、多方面的数据已准备好用于开发和训练高性能的诊断人工智能模型，提供将影像与设备性能和患者病史联系起来的全面视图。[14, 15, 16]
该数据集提供了对快速增长的全球医疗影像人工智能市场的访问权，该市场在 2025 年的估值为 21 亿美元，预计将以 23.9% 的复合年增长率增长。[3] 虽然访问需要遵守加拿大的 PHIPA/PIPEDA 法规以及潜在的共同所有权复杂性，但该临床验证数据的稀有性和深度为寻求在预计到 2035 年将达到 196 亿美元的市场中获得竞争优势的买家提供了重大机会。[3] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据受加拿大 PHIPA/PIPEDA 法规管辖；数据涉及临床培训和设备性能日志；可能与他们代表的医疗设备制造商存在数据共同所有权 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据证实 Venamed 拥有一个独特的、多模态的数据集，捕捉了血管通路手术的整个生命周期。该集合结合了手术医学影像、实时超声数据以及相关的供应链信息，提供了对这些关键干预措施的全面视图。这些专有数据是诊断人工智能公司开发影像引导疗法模型的首选资产，这是快速增长的 196 亿美元医疗影像人工智能市场中的一个关键增长领域。
See dimension details ↓- Dormant Data Surplus70
盈余=中等，5 个近期外部信号 — 超出已货币化的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 数据需求信号（0 类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dataset Specificity90
主导的“医疗记录”，行业医疗保健，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
高买家需求源于对精选医疗影像数据的迫切需求，以利用医疗影像人工智能市场预计的 23.9% 的复合年增长率。[3]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=拥有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - ICP Audit100
✓ 良好目标 — Vena Medical 是一个理想的目标，因为它制造和销售独特的医疗影像设备，作为其在临床环境中使用情况的副产品，生成专有的血管内视频数据，而它目前似乎并未将其货币化。问题：最初的来源描述“医疗影像数据集机会”具有误导性；该公司的核心产品是创建影像的医疗设备；数据是在现场医疗过程中生成的，这意味着数据采集存在重大的隐私、道德和监管障碍（例如，患者同意）。
- Deep Qualification90
⚠ 需要审查 — Vena Medical 是一家医疗设备制造商，其产品 MicroAngioscope 生成高度合理且有价值的医疗影像数据集；然而，该数据受到严格的加拿大健康法规（PHIPA/PIPEDA）的约束，并且可能涉及公司、医疗保健提供者和患者之间复杂的共同所有权。[商业模式 = 工具供应商；许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<figure><div><img src="https://imgproxy.divecdn.com/HDXCMuwpTo4W3TZPDuJxBKWjDpFEhQnan8PL_oR0GcQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9JbGx1bWluYS1idWlsZGluZy1lbnRyYW5jZS5qcGc=.webp" /></div></figure><p>The gene sequencing company this week named a new chief commercial officer and chief legal officer.</p>”
- “<p>ForSight Robotics' JASPER Platform assists surgeons with cataract surgeries, while still leaving the power in the surgeon's hands.</p> <p>The post <a href="https://www.therobotreport.com/forsight-robotics-road-to-performing-a-fully-robotic-cataracts-surgery/">ForSight Robotics’ road to performing a fully robotic cataract surgery</a> appeared first on <a href="https://www.therobotreport.com">The Robot Report</a>.</p>”
- “<p>With the acquisition of Robocath completed, Stereotaxis intends to accelerate development of next-generation robotic technologies for endovascular procedures.</p>”
Medical records / imaging
该数据集包含来自PICC 和 Midline 插入的手术影像，提供了临床技术和结果的视觉证据，对于训练诊断人工智能模型以识别手术成功非常有价值。
Procurement / tenders
该数据集包括专门的血管通路产品的详细供应链和库存记录，使人工智能买家能够将特定的医疗设备与手术数据和医院采购模式相关联。
IoT / sensor data
这些证据指向用于针头引导的超声系统的时间序列数据，为训练人工智能算法进行实时影像分析和手术导航提供了丰富、动态的输入。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Venamed Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $2.1 billion in 2025, projected to reach $19.6 billion by 2035, growing at a CAGR of 23.9% (source: Global Market Insights Inc.). [3]. Investment score 66.4/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Independentlogistics — 监管记录数据集机会
View opportunity →其他Evoenergy — 维护日志数据集机会
View opportunity →交通运输Hartmann International — API 可访问数据集机会
View opportunity →